Advisor Group Holdings, Inc. Adaptimmune Therapeutics PLC Transaction History
Advisor Group Holdings, Inc.
- $42.2 Billion
- Q3 2024
A detailed history of Advisor Group Holdings, Inc. transactions in Adaptimmune Therapeutics PLC stock. As of the latest transaction made, Advisor Group Holdings, Inc. holds 15,258 shares of ADAP stock, worth $10,680. This represents 0.0% of its overall portfolio holdings.
Number of Shares
15,258
Previous 15,258
-0.0%
Holding current value
$10,680
Previous $14,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding ADAP
# of Institutions
83Shares Held
150MCall Options Held
60.8KPut Options Held
5.8K-
Matrix Capital Management Company, LP Waltham, MA37.7MShares$26.4 Million1.71% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA27.4MShares$19.2 Million1.13% of portfolio
-
Nea Management Company, LLC Timonium, MD17.1MShares$12 Million1.24% of portfolio
-
Baillie Gifford & CO16.8MShares$11.7 Million0.01% of portfolio
-
Long Focus Capital Management, LLC San Juan, PR13.3MShares$9.31 Million0.46% of portfolio
About Adaptimmune Therapeutics PLC
- Ticker ADAP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 163,370,000
- Market Cap $114M
- Description
- Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...